Search results
Results from the WOW.Com Content Network
Recently classified as a disease, obesity leads to serious health problems, including diabetes, heart. The Motley Fool's health-care show Market Checkup focuses this week on obesity, one of ...
The U.S. medical establishment is clear about its stance on obesity: it is a “common, serious, and costly chronic disease,” as the U.S. Centers for Disease Control and Prevention puts it.By ...
The Childhood Obesity Task Force is a United States government task force charged with reducing childhood obesity in the United States. It was founded on February 9, 2010, by the Obama administration through a presidential memorandum, announcing the establishment of a Task Force on Childhood Obesity.
Management of obesity can include lifestyle changes, medications, or surgery. Although many studies have sought effective interventions, there is currently no evidence-based, well-defined, and efficient intervention to prevent obesity. [1] Treatment for obesity often consists of weight loss via healthy nutrition and increasing physical exercise.
[3] [4] [5] Let's Move! sought to decrease childhood obesity to 5% by 2030. [6] Despite its goal, the Let's Move! initiative did not cause a decline in obesity rates. In 2008, 68% of Americans were either overweight or obese. By 2016, that number jumped to 71.2%. In 2018, more than 73.1% of Americans were either overweight or obese. [7]
The NPLAN advocates for a soda tax, specifically an excise tax, and have published model legislation which earmarks the funds raised to go to programs to prevent and treat obesity. [5] According to the American Public Health Association, they provide "legal technical assistance focused on childhood obesity prevention policy." The Network has ...
The same scurvy-ish negligence shows up at every level of government. From marketing rules to antitrust regulations to international trade agreements, U.S. policy has created a food system that excels at producing flour, sugar and oil but struggles to deliver nutrients at anywhere near the same scale.
AstraZeneca moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive licence to develop an ...